InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on June 3, 2026 informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq. As previously di
Biotechnology, Pharmaceuticals
2026-06-04 5:00 PM EDT | InMed Pharmaceuticals
Envoy Medical to Present at Planet MicroCap Conference Las Vegas on June 16th-18th
White Bear Lake, Minnesota--(Newsfile Corp. - June 4, 2026) - Envoy Medical® Inc. (NASDAQ: COCH), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV. Planet MicroCap Las Vegas 2026 Dates: June 16-18, 2026 Location: Bellagio Hotel & Ca
Biotechnology, Healthcare and Hospitals
2026-06-04 8:30 AM EDT | Envoy Medical, Inc.
TempraMed Signs Agreement for Exclusive Distribution Partnership in Brazil, One of the Largest Diabetes and Biologics Markets Globally
Highlights TempraMed signs Agreement for exclusive distribution in Brazil with Mobil Saúde Comercial Ltda Brazil represents one of the world's largest markets for diabetes, GLP-1 therapies, and temperature-sensitive biologics1. Diabetes market alone reached USD $2.15 Billion in 2025 Partnership builds on TempraMed's recently granted Brazilian patent protecting th
Technology, Biotechnology, Pharmaceuticals, Health
2026-06-04 7:00 AM EDT | TempraMed Technologies Ltd.
Theralase(R) Lists Warrants on the TSXV
Toronto, Ontario--(Newsfile Corp. - June 3, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted for listing up to 20,399,050 common share p
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-06-03 7:00 AM EDT | Theralase Technologies Inc.
Restart Life Sciences Appoints Inez Ho as Chief Financial Officer
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2026) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSF) ("Restart Life" or the "Company") is pleased to announce the appointment of Inez Ho as Chief Financial Officer (CFO) of the Company, effective immediately. Ms. Ho brings over 12 years of robust finance and accounting experience to Restart Life, with a strong track record of supporting publicly listed companies across diverse industries. Her deep areas of e
Technology, Biotechnology, Health
2026-06-03 6:00 AM EDT | Restart Life Sciences Corp.
Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - June 3, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Beaver to its Board of Directors. Dr. Beaver brings more than two decades of leadership experience across global pharmaceutical and biotechnology organizations. Dr. Beaver has held senior leadership position
Biotechnology, Pharmaceuticals, Health
2026-06-03 3:15 AM EDT | Defence Therapeutics Inc.
iOrganBio Appoints Zhiping Pang, M.D., Ph.D., to Scientific Advisory Board
Chapel Hill, North Carolina--(Newsfile Corp. - June 2, 2026) - iOrganBio, an innovator in intelligent cell manufacturing that is redefining how human cells are engineered and reliably produced at scale for research and therapeutic applications, including FDA-aligned New Approach Methodologies (NAMs), today announced the appointment of Zhiping Pang, M.D., Ph.D., to its Scientific Advisory Board. Dr. Pang is one of the leading experts in human neuron biology, synaptic function,
2026-06-02 8:39 AM EDT | iOrganBio
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma
75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year overall survival data (75% vs. 60%, p = 0.034) Updated clinical efficacy data being added to regulatory dossiers as Company seeks early market authorizations in U.S., U.K., Europe and Australia in 2nd half of 2026 EMA and Australia TGA (TGA) alignment achieved on early Q4-202
2026-06-02 6:00 AM EDT | OS Therapies
Nextleaf Solutions Reports Fiscal Q2 2026 Results
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) ("Nextleaf" or the "Company") a multi-patented Canadian cannabis processor, announced financial results for Q2 FY2026 (ended March 31, 2026), with gross revenue of $3,338,310 and gross profit of $914,536 (38% gross margin). The quarter reflects deliberate investment in commercial infrastructure, including a national sales agency, qualified export ready platform, and a second
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-06-01 9:30 AM EDT | Nextleaf Solutions Ltd.
CBIH Completes Cannabinoid-Based Melanoma Patent Application Program Focused on Cannabinoid Science and Epigenetic Regulation
Houston, Texas--(Newsfile Corp. - June 1, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company focused on cannabinoid biotechnology, applied research, and therapeutic innovation, today announced the completion of a patent-ready melanoma research program focused on cannabinoid science, oncology biology, aging-related cellular stress, and epigenetic regulation. The Company views this milestone as part of its broader strategy to build research-driven int
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-06-01 7:00 AM EDT | Cannabis Bioscience International Holdings
Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to Its Board of Directors
Montreal, Quebec--(Newsfile Corp. - June 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Lambert to its Board of Directors, effective immediately. Dr. Lambert brings more than four decades of scientific leadership and pioneering expertise in the development of antibody-drug conjugates ("ADCs"), f
Biotechnology, Pharmaceuticals, Health
2026-06-01 3:15 AM EDT | Defence Therapeutics Inc.
Theralase(R) Releases Q1 2026 Financial Statements
Toronto, Ontario--(Newsfile Corp. - May 29, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancer, bacteria and viruses has released the Company's unaudited interim consolidated financial statements for the three-month period ended March
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-05-29 5:04 PM EDT | Theralase Technologies Inc.
Defence Therapeutics Strengthens Its Scientific Advisory Board with the Appointment of Dr. Sarkis Meterissian
Montreal, Quebec--(Newsfile Corp. - May 29, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, announces that Dr. Sarkis Meterissian resigned today from the Board of Directors of Defence to deepen engagement with the Company by joining the Scientific Advisory Board ("SAB"). Defence Therapeutics' current SAB is composed of Rob Leanna, PhD,
Biotechnology, Pharmaceuticals, Health
2026-05-29 4:30 PM EDT | Defence Therapeutics Inc.
Merci Dupre Clothiers Highlights Growing Concerns Around Environmental Pollutants with Innovative Enviremware Technology
Franklin, Tennessee--(Newsfile Corp. - May 29, 2026) - Recent national conversations about toxic chemicals in everyday products are reshaping how consumers evaluate what they wear, with growing scrutiny of substances such as BPA, PFAS "forever chemicals" and other compounds commonly found in textiles and performance fabrics. As awareness surrounding fabric safety and environmental exposure increases, Merci Dupre Clothiers is posit
Biotechnology, Food / Beverages, Health
2026-05-29 2:45 PM EDT | DRC Ventures
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World
New York and Rockville, Maryland--(Newsfile Corp. - May 29, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "th
2026-05-29 7:20 AM EDT | OS Therapies
MustGrow Announces First Quarter 2026 Financial Results
Investor Webcast: Friday, May 29th at 4:00pm ET / 1:00pm PT Register/View Here: https://us02web.zoom.us/webinar/register/7717781882447/WN_m6cQAgeQSD6hjP6JeVpfbw Please join/register at least 5 minutes prior to the call. Email questions before 2:00pm ET to info@mustgrow.ca, which will be addressed during the Q&A portion of the webcast.
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2026-05-28 5:00 PM EDT | MustGrow Biologics Corp.
PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines
Toronto, Ontario--(Newsfile Corp. - May 27, 2026) - PharmaTher Holdin
Biotechnology, Pharmaceuticals
2026-05-27 8:00 AM EDT | PharmaTher Holdings Ltd.
OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences
New York and Rockville, Maryland--(Newsfile Corp. - May 26, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies"
2026-05-26 7:40 AM EDT | OS Therapies
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - May 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-05-26 7:00 AM EDT | Phio Pharmaceuticals Corp.
Optimi Health Advances Highest-Purity Natural Psilocybin Extract to Date
Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN0) (the "Company" or "Optimi"), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced the completion of a production run of naturally derived psilocybin extract measuring approximately 6% psilocybin content, representing the highest-purity botanical ps
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-05-26 7:00 AM EDT | Optimi Health Corp.